News

Spero Therapeutics Receives FDA Approval for Phase 3 Clinical Trial of Tebipenem HBr

1 Mins read

Spero Therapeutics has obtained written agreement from the U.S. Food and Drug Administration (FDA) for a Special Protocol Assessment, which outlines the design and size of its pivotal Phase 3 clinical trial. This trial will evaluate the efficacy of tebipenem HBr in patients with complicated urinary tract infection (cUTI), including acute pyelonephritis.

In collaboration with GSK, Spero Therapeutics has developed tebipenem, aiming to introduce the first oral carbapenem antibiotic for the treatment of cUTI, subject to FDA approval.

The primary efficacy endpoint of this trial will be the overall response observed during the test-of-cure visit. The FDA has indicated that positive and compelling results from this trial, combined with previously conducted studies, may be sufficient to support the approval of tebipenem HBr as a treatment for cUTI, including pyelonephritis, with a limited use indication.

As part of its license agreement with GSK, Spero Therapeutics is eligible to receive milestone and royalty payments upon achieving certain development milestones. During the progression of the Phase 3 clinical trial, Spero Therapeutics could potentially receive up to $120 million in development milestones. Additional potential milestone payments include up to $150 million based on first commercial sales and up to $225 million based on sales performance. Furthermore, Spero Therapeutics will receive tiered royalties in the low-single digit to low-double digit range on tebipenem HBr sales worldwide, excluding Japan and certain Asian countries.

In premarket trading, Spero shares experienced an 8% increase, reaching $1.53.

Related posts
News

xrp price prediction: XRP Price Forecast: Market decline continues as SOPR resets. Here's current market trends, retail demand, technical analysis and analysts insights todayheadline | Today Headline

1 Mins read
XRP Price Forecast shows Ripple trading near $2.26 on Friday after four consecutive days of decline. The cross-border payment token has faced…
News

Form 13G JADE BIOSCIENCES For: 16 October By Investing.com

1 Mins read
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment…
News

Trump's 100% Tariffs On China Send Bitcoin, Ethereum, And Dogecoin Price Crashing. But One Coin Stands Out - Cryptopolitan

2 Mins read
The crypto market’s early-October rally stalled after President Trump reignited tensions with China by confirming a sweeping 100% tariff on Chinese imports…

Leave a Reply

Your email address will not be published. Required fields are marked *